New study highlights an unexplored HIV vax path

Using a computer model, researchers have been able to identify the unique genetic profile of people most likely to carry highly reactive sets of T cells, which makes them part an elite group of people who are naturally able to ward off HIV infections. While each individual in the group is known to carry large quantities of these T cells, anyone who can develop a new vaccine that can hunt them down and activate the T cells against HIV would be able to protect people with normal cell levels. "What we need to do with a vaccine is train bigger T-cell armies that will be there when a person first encounters the HIV virus," says Bruce Walker, director of the Ragon Institute for HIV research at Massachusetts General Hospital in Boston. Developing an effective HIV vaccine has been one of the most vexing issues in the industry, with repeated misfires. Report

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.